BSE: 524636
OXYGENTA PHARMACEUTICAL LIMITE
Manufactures and sells pharmaceutical products from a base in Telangana (manufacturing licence no. 10/MD/AP/2013/B/G). It is a subsidiary of Virupaksha Organics Limited, which acquired a 56.5% stake in June 2025 and continues open-market buying; the board is seeking shareholder approval for related-party sales and purchases with Virupaksha Organics of up to Rs 250 crore and for loans and guarantees of up to Rs 200 crore in FY 2026-27. The product mix is not disclosed in the filings, but the cost shape — 97.7% materials as a share of FY26 revenue — points to a formulation or trading-led model with limited value-added processing. Revenue was Rs 11,298.19 lakhs in FY26 (up 3.4% YoY) but the company posted a net loss of Rs 1,757.17 lakhs, with finance costs rising sharply (nearly 4x to Rs 245.50 lakhs in Q1 FY27). Q1 FY27 revenue surged 144% YoY to Rs 3,699.69 lakhs while the net loss narrowed to Rs 210.37 lakhs. Borrowings climbed to Rs 10,956.68 lakhs by year-end FY26 (from Rs 6,193.24 lakhs) and the ECLGS scheme was drawn for Rs 399 lakhs; equity has turned negative at Rs -4,268.68 lakhs. AR · MarketPing reader · 2026-08-03
Revenue streams, as the annual report describes them. Pharmaceutical products. Loss-making, materials-heavy small-cap pharmaceutical manufacturer with negative net worth and rising borrowings
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 61 | 31 | 40 | 109 | 113 |
| EBITDA (ex other income) | 2 | (8) | (10) | (10) | (15) |
| margin % | 3.3 | (25.3) | (24.4) | (9.4) | (13.6) |
| Owners' profit | (1) | (12) | (3) | (10) | (18) |
| EPS, as reported (₹) | (0.48) | (6.36) | (1.09) | 2.86 | 4.75 |
| ROE % · ROCE % | 1.8 · 1.8 | 25.0 · (35.0) | 17.3 · (41.6) | 40.2 · 352.8 | 41.2 · (51.8) |
| Debt / equity (x) | (1.51) | (1.47) | (2.84) | (2.43) | (2.57) |
| Cash from operations | (3) | (5) | (13) | 3 | (28) |
| Capex | (5) | (10) | (4) | (11) | (13) |
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14 | 33 | 49 | 15 | 14 | 34 | 50 | 37 |
| Profit before tax | (3) | (5) | (4) | (8) | (6) | (6) | (1) | (3) |
| Net profit | (3) | (4) | (2) | (6) | (5) | (5) | (2) | (2) |
| EPS (₹) | (0.81) | (1.07) | 0.60 | 1.65 | 1.33 | 1.32 | 0.45 | 0.57 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,49,869 | 37.2 | 5.36 | 24.1 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,49,683 | 85.5 | 14.90 | 64.4 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,282 | 79.4 | 9.57 | 41.6 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,16,367 | 26.0 | 3.93 | 15.0 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,11,403 | 33.0 | 3.23 | 17.1 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,08,995 | 99.6 | 20.07 | 60.7 | 16.4 | 17.2 | 7.2 | 32.0 |
| MANKIND PHARMA LIMITED | 1,00,400 | 49.1 | 6.06 | 27.6 | 11.7 | 10.8 | — | 27.3 |
| DR. REDDY S LABORATORIES | 1,00,367 | 31.1 | 2.63 | 13.5 | 10.9 | 13.0 | 12.1 | 15.0 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 14.5 | 29.6 | 41 of 170 | 76% |
| ROCE | (66.0) | 10.8 | 178 of 183 | 3% |
| ROE | 41.2 | 10.4 | 9 of 171 | 95% |
| Debt / Equity | (2.6) | 0.1 | 1 of 171 | 100% |
| EBITDA margin | 1.5 | 17.5 | 153 of 165 | 7% |
| Revenue growth | 144.4 | 16.3 | 6 of 161 | 97% |
| Profit growth | 65.5 | 30.9 | 52 of 158 | 68% |
| Market cap | 196 | 770 | 116 of 184 | 37% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 21 Aug 2026 · Oxygenta Pharma 33rd AGM: All 7 resolutions approved | board shareholder meetings | low | — | — |
| 21 Aug 2026 · Oxygenta Pharma 33rd AGM: all 7 resolutions passed including director appointments | board shareholder meetings | low | — | — |
| 31 Jul 2026 · Newspaper publication of 33rd AGM notice; AGM on 21 August 2026 | compliance | minimal | — | — |
| 30 Jul 2026 · Book Closure and E-Voting Cut-off Date for 33rd AGM | board shareholder meetings | low | — | — |
| 30 Jul 2026 · Oxygenta Pharma files 33rd Annual Report for FY 2025-26, AGM on Aug 21 | compliance | medium | — | — |
| 30 Jul 2026 · 33rd AGM notice with director appointments and related party transactions | board shareholder meetings | low | — | — |
| 27 Jul 2026 · Board approves Q1 FY27 results, appoints cost auditor, AGM on 21 Aug | management changes | medium | — | — |
| 27 Jul 2026 · Q1 FY27 revenue up 144 percent YoY, net loss narrows to Rs 210 lakhs | results | high | — | — |
| 27 Jul 2026 · Q1 FY27 results: Revenue up 144% YoY, losses narrow | results | medium | — | — |
| 24 Jul 2026 · Board meeting postponed from 25 July to 27 July 2026 | results | low | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.